Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Starts Presentation at 30th Annual ROTH Conference
Tonix Pharmaceuticals (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmaceutical products to treat serious neuropsychiatric conditions and focused on improving biodefense through developing potential medical counter-measures. The company’s lead product candidate, Tonmya, or TNX-102 SL, is in phase 3 development as a bedtime treatment for PTSD and is also being developed as a bedtime treatment for agitation in Alzheimer’s patients. Tonmya has undergone a pre-IND (Investigational New Drug) meeting with the FDA, and the company’s TNX-601 (tianeptine oxalate) is in the pre-IND application stage for daytime dosing to treat PTSD. The company’s lead…







